FMC reported adjusted fourth-quarter earnings of $1.20 per share, missing the consensus by $0.01 and down 33% year-over-year from $1.79, while revenue declined 11.5% to $1.08 billion versus analysts’ $1.15 billion forecast. The company recorded a negative net margin of 64.57% on a GAAP basis and a positive return on equity of 8.83%. Shares gapped down at the open, moving from a prior close of $16.99 to $15.09, before settling in heavy volume of over 6.1 million shares traded as investors reacted to both the EPS shortfall and the steep annual revenue contraction.

Management set first-quarter 2026 adjusted EPS guidance between –$0.44 and –$0.32, well below the Street’s ~$0.11 estimate, citing $20 million of tariff charges and mid-single-digit price headwinds. Full-year 2026 adjusted EPS is forecast at $1.63–1.89, versus consensus near $2.38, with revenue guidance of $3.60 billion to $3.80 billion (versus ~$3.9 billion expected) reflecting a 5% decline at the midpoint. The outlook implies multiquarter recovery is required, as volume gains from new active ingredients are offset by the post-patent decline in Rynaxypyr® and legacy portfolio pressure.

FMC’s board has authorized a strategic-options review, including potential sale scenarios, aiming to unlock value and strengthen the balance sheet. The company targets $1 billion of debt reduction through asset divestitures and licensing, having already agreed to sell its India commercial business. Moody’s recent downgrade to junk status, driven by patent expiry risks around Rynaxypyr®, raises refinancing costs and heightens execution risk. Despite select insider purchases and a mix of buy/outperform ratings from analysts, investor concern persists over cash-flow sustainability and timing of any strategic transaction.